GLP-1 agonists show short-term metabolic benefit in PCOS but reproductive effects remain uncertain

Photo by Brett Jordan / Unsplash

Frontiers in Medicine Published June 2, 2026 Medically reviewed June 2, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider GLP-1RAs for short-term metabolic optimization in PCOS, but reproductive benefits remain unconfirmed.

This publication is a narrative synthesis with Bayesian network meta-analysis of GLP-1 receptor agonists in Polycystic Ovary Syndrome (PCOS). The scope covers short-term metabolic and reproductive outcomes from trials with 12–16 weeks follow-up.

The main finding is relatively robust support for short-term metabolic benefit, specifically body-weight change. However, reproductive outcomes including ovulation, clinical pregnancy, time to pregnancy, and live birth were inconsistently defined and sparsely reported across trials. No confirmatory quantitative synthesis or treatment ranking was undertaken for these outcomes.

Limitations noted by the authors include heterogeneous findings, lack of standardized clinical pathways, and substantially greater uncertainty for reproductive translation and periconception safety. Preconception washout is required, and no data on adverse events or tolerability were reported.

Practice relevance: GLP-1RAs should be positioned as time-limited, preconception metabolic-optimization tools, not as confirmed fertility-enhancing therapies. Their use in PCOS fertility care should be individualized through shared decision-making, with explicit discussion of the difference between established metabolic benefit and hypothesis-generating reproductive benefit.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

BackgroundGLP-1 receptor agonists (GLP-1RAs) address key metabolic drivers of Polycystic Ovary Syndrome (PCOS), yet their integration into fertility management remains challenging because reproductive efficacy is variably reported, preconception washout is required, and standardized clinical pathways are lacking.Main bodyWe present a structured, fertility-centered, hypothesis-generating narrative synthesis of the metabolic–reproductive–pregnancy continuum in PCOS, integrating evidence from randomized trials, observational studies, reviews, and clinical guidance. Heterogeneous findings are organized by intervention/comparator, follow-up window, and key effect modifiers, including baseline obesity/insulin-resistance phenotype, concomitant metformin, and lifestyle co-interventions. The clinical framework is derived from this narrative synthesis rather than from quantitative reproductive meta-analysis. As a methodological proof-of-concept only, we additionally performed a Bayesian network meta-analysis restricted to body-weight change within a prespecified 12–16-weeks window in the largest connected treatment network. Because ovulation, clinical pregnancy, time to pregnancy, and live birth were inconsistently defined and sparsely reported across trials, no confirmatory quantitative synthesis or treatment ranking was undertaken for these reproductive outcomes. We therefore distinguish evidence domains explicitly, with relatively robust support for short-term metabolic benefit but substantially greater uncertainty for reproductive translation and periconception safety.ConclusionThe narrative evidence supports positioning GLP-1RAs as time-limited, preconception metabolic-optimization tools, not as confirmed fertility-enhancing therapies per se. Their use in PCOS fertility care should be individualized through shared decision-making, with explicit discussion of the difference between established metabolic benefit and hypothesis-generating reproductive benefit, together with drug-specific washout planning and strategies to minimize post-discontinuation rebound. Future trials should standardize reproductive endpoints and systematically capture periconception exposure to enable confirmatory synthesis and individualized benefit–risk estimation.